All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2018; the latest 2024-02-28.
From the record
Mirum Pharmaceuticals, Inc.'s filings since 2018 show 1 warning event: a late-report notice (Form NT 10-K or NT 10-Q, the latest 2024-02-28) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+128.5% a year over 5 filed years; profitable in 0 of 5.
From the record
Mirum Pharmaceuticals, Inc.'s 5 filed years say what it did: revenue went from $19 million in fiscal 2021 to $521 million in fiscal 2025, up 128.5% a year; it rose in 4 of 4 years; it never fell from a peak; net income was positive in 0 of 5 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 5.8/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Mirum Pharmaceuticals, Inc.'s shareholder treatment is put at 5.8 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 42% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -7%: lost 7¢ per shareholder dollar. Leverage 63%: owes 63¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Mirum Pharmaceuticals, Inc. lost about 7 cents for every dollar of shareholders' money. Leverage: it owed about 63 cents per dollar of assets, and net share issuance: its share count grew 5.6% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 20% of 315 in its family; net margin -4.5%.
From the record
Mirum Pharmaceuticals, Inc.'s standing among 315 graded names in its industry family: revenue of $521 million in fiscal 2025 ranks in the top 19% by size; a net margin of -4.5% ranks in the top 26%; revenue growth of 89.1% a year over the last 3 filed years ranks in the top 16% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 36% of 315 in its family for leadership; chief executive since 2019.
From the record
Mirum Pharmaceuticals, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Peetz, Christopher (CHIEF EXECUTIVE OFFICER, as filed), filing under that title since 2019-07-17, 7.3 years (top 28% of its family); the 14 officers and directors filing in the last fifteen months have been on the record a median of 4.8 years (bottom 32%); 2 officer or director changes were reported on Form 8-K since 2023-11-13, against the 14 people in charge now (top 11%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 42% of 273 in its family for room to expand.
From the record
Mirum Pharmaceuticals, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $297 million against no long-term debt tagged leaves 35.2% of its assets as net cash, top 42% of its family; cash from operations less capital spending is 10.5% of revenue (top 20%); research spending of 35.7% of revenue (bottom 37%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 37% of 306 in its family for growth drivers.
From the record
Mirum Pharmaceuticals, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 89.1% a year over the last three filed years against 128.5% over all 5, slowing (bottom 15% of its family); the newest year grew 54.8% (top 24%); research spending grew 20.3% a year (top 23%); capital spending grew 50.8% a year (top 14%) (its annual reports). Mirum Pharmaceuticals, Inc. reported 2 product lines in fiscal 2025: Livmarli at $360 million (69%), Bile Acid Medicines at $161 million (31%); 2 of 2 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 41% of 233 in its family for expectations against reality.
From the record
Mirum Pharmaceuticals, Inc.'s newest year against its own record: revenue of $521 million in fiscal 2025 came in 26% below the $704 million its prior three years' pace pointed to (bottom 29% of its family); net income of $23 million against a prior three-year average of $129 million (top 21%); a net margin of -4.5% against -96.6% before (top 33%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made